Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-12-03
DOI
10.1186/s13045-020-01001-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study
- (2020) Lingzhi Yan et al. BLOOD
- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
- (2020) Deepu Madduri et al. BLOOD
- Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2020) Bai-Yan Wang et al. BLOOD
- A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial
- (2020) Chenggong Li et al. BLOOD
- Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
- (2020) Chunrui Li et al. BLOOD
- Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma
- (2020) Andrew J. Cowan et al. BLOOD
- Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma
- (2020) Xin Yao et al. BLOOD
- Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
- (2020) Jesus G. Berdeja et al. BLOOD
- B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
- (2020) Nina Shah et al. LEUKEMIA
- Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
- (2020) Norris Lam et al. Nature Communications
- Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
- (2020) Gils Roex et al. Pharmaceutics
- Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
- (2020) Nikhil C. Munshi et al. JOURNAL OF CLINICAL ONCOLOGY
- KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.
- (2020) Sundar Jagannath et al. JOURNAL OF CLINICAL ONCOLOGY
- BCMA-targeted immunotherapy for multiple myeloma
- (2020) Bo Yu et al. Journal of Hematology & Oncology
- CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
- (2019) Mohamad Hamieh et al. NATURE
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.
- (2019) Lu Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hypoxia Selectively Impairs CAR-T Cells In Vitro
- (2019) Robert Berahovich et al. Cancers
- Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
- (2019) Marijke Timmers et al. Frontiers in Immunology
- Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted chimeric antigen receptor-T cells for B-cell non-Hodgkin lymphoma
- (2019) Zhitao Ying et al. Molecular Therapy-Oncolytics
- Efficacy and Safety of CAR-T Therapy with Safety Switch Targeting Bcma for Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Clinical Study
- (2019) Weijun Fu et al. BLOOD
- T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma
- (2019) Lekha Mikkilineni et al. BLOOD
- Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma
- (2019) Jin Jie et al. BLOOD
- Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
- (2019) Alfred L. Garfall et al. BLOOD
- Potent Anti-Tumor Activity of Bcma CAR-T Therapy Against Heavily Treated Multiple Myeloma and Dynamics of Immune Cell Subsets Using Single-Cell Mass Cytometry
- (2019) Yongxian Hu et al. BLOOD
- Updated Phase 1 Results of a First-in-Human Open-Label Study of Lcar-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (Bcma)
- (2019) Lijuan Chen et al. BLOOD
- Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM
- (2019) Xiaolan Shi et al. BLOOD
- A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
- (2019) Hua Zhang et al. BLOOD
- Chimeric antigen receptor T cell therapies for multiple myeloma
- (2019) Chao Wu et al. Journal of Hematology & Oncology
- Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
- (2019) Mattia D’Agostino et al. LEUKEMIA
- A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
- (2019) Zhiling Yan et al. Lancet Haematology
- B cell maturation antigen‐specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta‐analysis
- (2019) Nico Gagelmann et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- CARs and other T cell therapies for MM: The clinical experience
- (2018) Sophia Danhof et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets
- (2018) Hanley N. Abramson Clinical Lymphoma Myeloma & Leukemia
- Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival
- (2018) Ingemar Turesson et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
- (2018) Bianca D. Santomasso et al. Cancer Discovery
- bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.
- (2018) Noopur S. Raje et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytokine release syndrome: grading, modeling, and new therapy
- (2018) Delong Liu et al. Journal of Hematology & Oncology
- Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
- (2018) Shih-Feng Cho et al. Frontiers in Immunology
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
- (2018) Jinhuan Xu et al. Journal of Hematology & Oncology
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- New Chimeric Antigen Receptor Design for Solid Tumors
- (2017) Yuedi Wang et al. Frontiers in Immunology
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Multiple myeloma
- (2015) Christoph Röllig et al. LANCET
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back
- (2014) Giada Bianchi et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple myeloma
- (2010) M. A. Dimopoulos et al. ANNALS OF ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now